Secukinumab: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Subcutaneous
Plaque psoriasis

Adult: 300 mg every week for 5 doses, followed by 300 mg every month. Each 300 mg dose is given as 2 injections of 150 mg. Review treatment if no response within 16 weeks of initial dose.

Subcutaneous
Psoriatic arthritis

Adult: 150 mg every week for 5 doses, followed by 150 mg every month, may increase to 300 mg if response is inadequate. Coexistent moderate to severe plaque psoriasis or anti-TNFα inadequate responders: 300 mg every week for 5 doses, followed by 300 mg every month. Review treatment if there is no response after 16 weeks.

Subcutaneous
Ankylosing spondylitis

Adult: 150 mg once weekly for 5 weeks, then once monthly thereafter. Review treatment if there is no response after 16 weeks.

Reconstitution

Powd for inj: Reconstitute 150 mg vial w/ 1 mL sterile water for inj to make a 150 mg/mL soln.

Contraindications

Serious infections (e.g. active TB, hepatitis B, sepsis). Admin of live vaccines.

Special Precautions

Patient w/ history of recurrent or chronic infection, inflammatory bowel disease (e.g. Crohn’s disease). Pregnancy and lactation.

Adverse Reactions

Significant: Infections (e.g. upper resp tract infections, mucocutaneous candida infection). Rarely, inflammatory bowel disease, hypersensitivity reactions (e.g. anaphylaxis).
Nervous: Flu-like symptoms.
GI: Diarrhoea.
Resp: Rhinorrhoea.
Endocrine: Menstrual disorders (e.g. irregular menses, dysmenorrhoea).
Haematologic: Neutropenia.
Ophthalmologic: Conjunctivitis.
Otic: Otitis externa.
Dermatologic: Tinea pedis, urticaria.

Pregnancy Category (US FDA)

SC: B

Monitoring Parameters

Monitor for signs and symptoms of infection, active TB, and inflammatory bowel disease. Perform screening test for TB prior to initiation of therapy.

Drug Interactions

May enhance the adverse effects and diminish the therapeutic effect of live vaccines.

Action

Description:
Mechanism of Action: Secukinumab is a recombinant fully human IgG1_/K monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines, chemokines, and mediators of tissue damage.
Pharmacokinetics:
Absorption: Bioavailability: 55-77%. Time to peak plasma concentration: Approx 6 days.
Distribution: Volume of distribution: 7.1-8.6 L.
Metabolism: Expected to be degraded into small peptides and amino acids via catabolic pathways.
Excretion: Elimination half-life: 22-31 days.

Storage

Store between 2-8°C. Do not freeze. Protect from light.
Any unused portions should be disposed of in accordance w/ local requirements.

MIMS Class

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Psoriasis, Seborrhea & Ichthyosis Preparations

ATC Classification

L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

References

Anon. Secukinumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/06/2017.

Buckingham R (ed). Secukinumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/06/2017.

Cosentyx Injection (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/06/2017.

Joint Formulary Committee. Secukinumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/06/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Secukinumab. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 01/06/2017.

Disclaimer: This information is independently developed by MIMS based on Secukinumab from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com